Latest Period
Q1 2026
Security Snapshot
Pharvaris N.V. - Ordinary Shares, par value Euro 0.12 per share (PHVS) Institutional Ownership
CUSIP: N69605108
13F Institutional Holders and Ownership History from Q1 2021 to Q1 2026
Institutions Reporting
110
Shares (Excl. Options)
58,921,412
Price
$28.25
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Ordinary Shares, par value Euro 0.12 per share
- Symbol
- PHVS on Nasdaq
- Shares outstanding
- 65,237,679
- Price per share
- $28.22
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 58,921,412
- Total reported value
- $1,664,385,298
- % of total 13F portfolios
- 0%
- Share change
- -229,999
- Value change
- -$6,360,608
- Number of holders
- 110
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- PHVS - Pharvaris N.V. - Ordinary Shares, par value Euro 0.12 per share is tracked under CUSIP N69605108.
- 110 institutions reported positions in Q1 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 107 to 110 between Q4 2025 and Q1 2026.
- Reported value moved from $1,638,008,634 to $1,664,385,298.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 110 institutions filings for Q1 2026.
Investment Quick Answers
What is CUSIP N69605108?
CUSIP N69605108 identifies PHVS - Pharvaris N.V. - Ordinary Shares, par value Euro 0.12 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q1 2026 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP N69605108:
Significant Owners of Pharvaris N.V. - Ordinary Shares, par value Euro 0.12 per share (PHVS) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| VIKING GLOBAL INVESTORS LP | 5.6% | $103,206,008 | 3,653,310 | VIKING GLOBAL INVESTORS LP | 31 Mar 2026 | |||
| Venrock Healthcare Capital Partners III, L.P. | 3.8% | $51,436,214 | 2,047,620 | Venrock Healthcare Capital Partners III, L.P. | 30 Jun 2025 | |||
| Bain Capital Life Sciences Fund, L.P. | 2.5% | -17% | $41,020,425 | -$5,670,300 | 1,640,817 | -12% | Bain Capital Life Sciences Fund, L.P. | 31 Dec 2025 |
As of 31 Mar 2026, 110 institutional investors reported holding 58,921,412 shares of Pharvaris N.V. - Ordinary Shares, par value Euro 0.12 per share (PHVS). This represents 90% of the company’s total 65,237,679 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Pharvaris N.V. - Ordinary Shares, par value Euro 0.12 per share (PHVS) together control 81% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| GENERAL ATLANTIC, L.P. | 12% | 8,031,252 | 0% | 11% | $226,882,869 |
| FMR LLC | 9.6% | 6,284,472 | -1.8% | 0.01% | $177,536,335 |
| Foresite Capital Management IV, LLC | 7.3% | 4,778,581 | 0% | 57% | $134,994,913 |
| venBio Partners LLC | 7.1% | 4,639,304 | 0% | 47% | $131,060,338 |
| VIKING GLOBAL INVESTORS LP | 5.6% | 3,653,310 | 0% | 0.29% | $103,206,008 |
| EQT Fund Management S.a r.l. | 5.2% | 3,424,609 | 0% | 9.5% | $96,745,204 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 4.8% | 3,126,042 | 0% | 1% | $88,310,687 |
| Bain Capital Life Sciences Investors, LLC | 4.1% | 2,675,509 | -4.5% | 6.8% | $75,583,129 |
| WELLINGTON MANAGEMENT GROUP LLP | 3.2% | 2,118,900 | +11% | 0.01% | $59,858,926 |
| Commodore Capital LP | 2.9% | 1,918,970 | +1.6% | 3.1% | $54,210,903 |
| NOVO HOLDINGS A/S | 2.7% | 1,750,000 | 0% | 4% | $49,437,500 |
| Saturn V Capital Management LP | 1.8% | 1,201,402 | +5.4% | 6.1% | $33,939,606 |
| Point72 Asset Management, L.P. | 1.5% | 1,007,016 | +42% | 0.05% | $28,448,202 |
| Cormorant Asset Management, LP | 1.5% | 1,000,000 | -7.7% | 1.4% | $28,250,000 |
| Sofinnova Investments, Inc. | 1.3% | 818,328 | +9.8% | 1.2% | $23,117,766 |
| 5AM Venture Management, LLC | 1.2% | 797,600 | 0% | 6.3% | $22,532,200 |
| Polar Capital Holdings Plc | 1.2% | 781,016 | +228% | 0.1% | $22,063,702 |
| BlackRock, Inc. | 1.2% | 757,213 | +6.9% | 0% | $21,391,267 |
| Soleus Capital Management, L.P. | 1.1% | 702,052 | 0% | 0.8% | $19,832,969 |
| Rock Springs Capital Management LP | 0.99% | 645,533 | +3.6% | 1.1% | $18,236,307 |
| Kynam Capital Management, LP | 0.98% | 640,395 | 0% | 1.1% | $18,091,159 |
| Patient Square Capital LP | 0.76% | 493,000 | -9.2% | 2.5% | $13,927,250 |
| Ikarian Capital, LLC | 0.75% | 486,856 | 0% | 2% | $13,753,683 |
| Elmind Capital, LP | 0.73% | 475,750 | 0% | 3.8% | $13,439,938 |
| Balyasny Asset Management L.P. | 0.71% | 462,251 | -6.9% | 0.03% | $13,058,591 |
Institutional Holders of Pharvaris N.V. - Ordinary Shares, par value Euro 0.12 per share (PHVS) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 58,921,412 | $1,664,385,298 | -$6,360,608 | $28.25 | 110 |
| 2025 Q4 | 59,040,212 | $1,638,008,634 | +$19,048,600 | $27.75 | 107 |
| 2025 Q3 | 57,844,608 | $1,443,142,875 | +$236,461,176 | $24.95 | 83 |
| 2025 Q2 | 45,040,180 | $792,712,813 | +$1,806,103 | $17.60 | 60 |
| 2025 Q1 | 44,939,067 | $705,543,867 | +$4,132,739 | $15.70 | 52 |
| 2024 Q4 | 44,644,168 | $855,824,077 | -$7,190,155 | $19.17 | 54 |
| 2024 Q3 | 45,045,428 | $834,243,398 | +$34,119,580 | $18.52 | 51 |
| 2024 Q2 | 43,008,763 | $808,565,649 | +$10,680,383 | $18.80 | 36 |
| 2024 Q1 | 42,425,740 | $980,459,437 | +$36,728,417 | $23.11 | 35 |
| 2023 Q4 | 40,745,703 | $1,142,917,292 | +$327,949,428 | $28.05 | 36 |
| 2023 Q3 | 29,067,102 | $606,630,419 | +$4,468,799 | $20.87 | 21 |
| 2023 Q2 | 28,913,752 | $441,577,880 | +$109,619,000 | $15.14 | 21 |
| 2023 Q1 | 21,781,494 | $173,888,454 | +$3,756,313 | $8.06 | 21 |
| 2022 Q4 | 21,301,855 | $239,644,411 | -$1,830,525 | $11.25 | 25 |
| 2022 Q3 | 22,314,954 | $173,600,000 | -$317,120 | $7.67 | 21 |
| 2022 Q2 | 22,353,338 | $494,009,000 | +$14,911,660 | $22.10 | 20 |
| 2022 Q1 | 21,685,388 | $397,090,000 | +$838,867 | $18.14 | 22 |
| 2021 Q4 | 21,647,018 | $321,068,000 | -$1,695,268 | $14.39 | 22 |
| 2021 Q3 | 21,631,638 | $380,302,000 | -$6,827,497 | $17.73 | 25 |
| 2021 Q2 | 21,995,815 | $406,288,000 | -$1,442,853 | $18.62 | 28 |
| 2021 Q1 | 22,025,122 | $616,507,000 | +$616,507,000 | $27.99 | 33 |